Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Comment by TriumphSpitSixon Dec 03, 2020 8:49pm
129 Views
Post# 32034282

RE:RE:RE:RE:Just a reminder-

RE:RE:RE:RE:Just a reminder-Have been reading the pleadings in the Orange County, Florida case... Check out Hemostemix's attorneys blasting the rhetorical flame thrower:


What  Aspire  has  attempted  to  do  now  goes  far  beyond  its  faade  of victimhood  to  now  seeking  to  make  the  Court  complicit  in  its  fraud.   Aspire  is entitled to no bond and any fees allegedly incurred are the product of Aspire’s own actions  in  pursuing  these  frivolous  claims.    Aspire’s  conduct  is  properly  cast  as follows: Aspire improperly holds Hemostemix’s clinical data and assets hostage — which Aspire concedes is owned by Hemostemix (see Compl., ¶ 8); it infringes on and  impedes  Hemostemix’s  clinical  trial  in  an  effort  to  extort  money  from Hemostemix;  it  then  sues  Hemostemix  in  a  foreign  jurisdiction  for  frivolous “injunctive” claims that are actually monetary claims in furtherance of this extortion scheme;  and  then  it  seeks  to  have  this  Court  impose  utterly  unsupported  and untenable damages on Hemostemix without ever properly serving Hemostemix and without even having a monetary judgment rendered.  Nothing about Aspire’s claims can  be  credited;  they  are  patently  dishonest.    The  Court  should  reject  Aspire’s contention, grant the stay and permit Hemostemix to seek recovery of fees and costs from Aspire and its counsel for frivolous and vexatious positions before this Court.
<< Previous
Bullboard Posts
Next >>